Special Drug Use-results Surveillance of Tafinlar/Mekinist
NCT06262919
·
clinicaltrials.gov ↗
RECRUITING
Status
110
Enrollment
INDUSTRY
Sponsor class
Conditions
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Interventions
DRUG:
Tafinlar/Mekinist
Sponsor
Novartis Pharmaceuticals